Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma-Reference-Cited by-同舟云学术

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

Published:2003-07-18 Issue:3 Volume:98 Page:542-553
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Danson Sarah,Middleton Mark R.,O'Byrne Kenneth J.,Clemons Mark,Ranson Malcolm,Hassan Jurjees,Anderson Heather,Burt Paul A.,Fairve-Finn Corrine,Stout Ronald,Dowd Isabel,Ashcroft Linda,Beresford Cheryl,Thatcher Nicholas

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference40 articles.

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

2. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

3. Chemotherapy in non-small cell lung cancer

4. National Institute for Clinical Excellence. Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer. Technology appraisal guidance, no.26. London: National Institute of Clinical Excellence, 2001.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study;Journal for ImmunoTherapy of Cancer;2024-03

2. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status;Cochrane Database of Systematic Reviews;2023-07-07

3. Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment;Patient Preference and Adherence;2022-01

4. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines;Journal of Modern Oncology;2021-11-19

5. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update;ESMO Open;2021-10